trial · primary record
Riliprubart Prefilled Pen (PFP)
Polyneuropathy, Inflammatory Demyelinating, Chronic
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 300 |
| Primary completion | 2029-10-03 |
| Primary endpoint | Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study period |
| Registry ID | NCT06859099 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:10.051Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06859099
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.